These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
170 related articles for article (PubMed ID: 31291250)
1. Direct medical and non-medical costs of a one-year care pathway for early operable breast cancer: Results of a French multicenter prospective study. Héquet D; Huchon C; Soilly AL; Asselain B; Berseneff H; Trichot C; Combes A; Alves K; Nguyen T; Rouzier R; Baffert S PLoS One; 2019; 14(7):e0210917. PubMed ID: 31291250 [TBL] [Abstract][Full Text] [Related]
2. Multidimensional impact of breast cancer screening: Results of the multicenter prospective optisoins01 study. Cariou A; Rouzier R; Baffert S; Soilly AL; Hequet D PLoS One; 2018; 13(8):e0202385. PubMed ID: 30138470 [TBL] [Abstract][Full Text] [Related]
3. Determinants of return at work of breast cancer patients: results from the OPTISOINS01 French prospective study. Arfi A; Baffert S; Soilly AL; Huchon C; Reyal F; Asselain B; Neffati S; Rouzier R; Héquet D BMJ Open; 2018 May; 8(5):e020276. PubMed ID: 29776920 [TBL] [Abstract][Full Text] [Related]
4. The patient-breast cancer care pathway: how could it be optimized? Baffert S; Hoang HL; Brédart A; Asselain B; Alran S; Berseneff H; Huchon C; Trichot C; Combes A; Alves K; Koskas M; Nguyen T; Roulot A; Rouzier R; Héquet D BMC Cancer; 2015 May; 15():394. PubMed ID: 25963161 [TBL] [Abstract][Full Text] [Related]
5. Absenteeism and indirect costs during the year following the diagnosis of an operable breast cancer: A prospective multicentric cohort study. Ferrier C; Thebaut C; Levy P; Baffert S; Asselain B; Rouzier R; Hequet D J Gynecol Obstet Hum Reprod; 2021 Jun; 50(6):101871. PubMed ID: 32673814 [TBL] [Abstract][Full Text] [Related]
6. Use of data-mining to support real-world cost analyses: An example using HER2-positive breast cancer in Iran. Ansaripour A; Zendehdel K; Tadayon N; Sadeghi F; Uyl-de Groot CA; Redekop WK PLoS One; 2018; 13(10):e0205079. PubMed ID: 30273393 [TBL] [Abstract][Full Text] [Related]
7. Treatment patterns, clinical outcomes and health care costs associated with HER2-positive breast cancer with central nervous system metastases: a French multicentre observational study. Baffert S; Cottu P; Kirova YM; Mercier F; Simondi C; Bachelot T; Le Rhun E; Levy C; Gutierrez M; Madranges N; Moldovan C; Coudert B; Spaëth D; Serin D; Cotté FE; Benjamin L; Maillard C; Laulhere-Vigneau S; Durand-Zaleski I BMC Health Serv Res; 2013 Oct; 13():456. PubMed ID: 24176086 [TBL] [Abstract][Full Text] [Related]
8. The Direct and Indirect Costs of Breast Cancer in Poland: Estimates for 2017-2019. Seweryn M; Banas T; Augustynska J; Lorenc O; Kopel J; Pluta E; Skora T Int J Environ Res Public Health; 2022 Dec; 19(24):. PubMed ID: 36554267 [TBL] [Abstract][Full Text] [Related]
9. Economic burden of chemotherapy-treated recurrent and/or metastatic squamous cell carcinoma of the head and neck in France: real-world data from the permanent sample of national health insurance beneficiaries. Lafuma A; Cotté FE; Le Tourneau C; Emery C; Gaudin AF; Torreton E; Gourmelen J; Bonastre J J Med Econ; 2019 Jul; 22(7):698-705. PubMed ID: 30895832 [No Abstract] [Full Text] [Related]
10. Economic burden of resected (stage IB-IIIA) non-small cell lung cancer in France, Germany and the United Kingdom: A retrospective observational study (LuCaBIS). Andreas S; Chouaid C; Danson S; Siakpere O; Benjamin L; Ehness R; Dramard-Goasdoue MH; Barth J; Hoffmann H; Potter V; Barlesi F; Chirila C; Hollis K; Sweeney C; Price M; Wolowacz S; Kaye JA; Kontoudis I Lung Cancer; 2018 Oct; 124():298-309. PubMed ID: 29961557 [TBL] [Abstract][Full Text] [Related]
11. [Episode-based bundled payment model: evaluation of medical costs for early operable breast cancer]. Majou D; Mekarnia Y; Martin B; Rouzier R; Héquet D Bull Cancer; 2021 Dec; 108(12):1091-1100. PubMed ID: 34657725 [TBL] [Abstract][Full Text] [Related]
12. Cost of treatment for breast cancer in central Vietnam. Hoang Lan N; Laohasiriwong W; Stewart JF; Tung ND; Coyte PC Glob Health Action; 2013 Feb; 6():18872. PubMed ID: 23394855 [TBL] [Abstract][Full Text] [Related]
13. [Standard treatment cost of female breast cancer at different TNM stages]. Li H; Huang Y; Huang R; Li JY Zhonghua Zhong Liu Za Zhi; 2013 Dec; 35(12):946-50. PubMed ID: 24506967 [TBL] [Abstract][Full Text] [Related]
14. Indirect costs associated with metastatic breast cancer. Wan Y; Gao X; Mehta S; Wang Z; Faria C; Schwartzberg L J Med Econ; 2013 Oct; 16(10):1169-78. PubMed ID: 23866016 [TBL] [Abstract][Full Text] [Related]
15. [Macro-economic calculation of spending versus micro-economic follow-up of costs of breast cancer]. Borella L; Paraponaris A Rev Epidemiol Sante Publique; 2002 Dec; 50(6):581-92. PubMed ID: 12515928 [TBL] [Abstract][Full Text] [Related]
16. Productivity losses and public finance burden attributable to breast cancer in Poland, 2010-2014. Łyszczarz B; Nojszewska E BMC Cancer; 2017 Oct; 17(1):676. PubMed ID: 29017454 [TBL] [Abstract][Full Text] [Related]
17. Healthcare costs associated with breast cancer in Germany: a claims data analysis. Kreis K; Plöthner M; Schmidt T; Seufert R; Schreeb K; Jahndel V; Maas S; Kuhlmann A; Zeidler J; Schramm A Eur J Health Econ; 2020 Apr; 21(3):451-464. PubMed ID: 31897812 [TBL] [Abstract][Full Text] [Related]
18. The cost of newly diagnosed breast cancer in Lithuania, 2011. Ivanauskienė R; Domeikienė A; Kregždytė R; Milašauskienė Ž; Padaiga Ž Medicina (Kaunas); 2015; 51(1):63-8. PubMed ID: 25744777 [TBL] [Abstract][Full Text] [Related]
19. Diagnostic and therapeutic approaches for nonmetastatic breast cancer in Canada, and their associated costs. Will BP; Le Petit C; Berthelot JM; Tomiak EM; Verma S; Evans WK Br J Cancer; 1999 Mar; 79(9-10):1428-36. PubMed ID: 10188886 [TBL] [Abstract][Full Text] [Related]
20. Cost of breast cancer based on real-world data: a cancer registry study in Italy. Capri S; Russo A BMC Health Serv Res; 2017 Jan; 17(1):84. PubMed ID: 28122558 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]